Product Pathways - Apoptosis
- Molecular Formula:
- Molecular Weight:
- 588.56 g/mol
Directions for Use
Etoposide is supplied as a lyophilized powder. For a 50 mM stock, reconstitute the 5.9 mg in 200 µl DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 5-50 µM for 4-24 hr. Soluble in DMSO at 100 mg/ml; very poorly soluble in ethanol and water with maximum solubility in water ~20-50 µM.
Western blot analysis of extracts from Jurkat cells, untreated (-) or etoposide-treated (25 μM, overnight; +), using Cleaved PARP (Asp214) (D64E10) XP® Rabbit mAb #5625 (upper) or total PARP Antibody #9542 (lower).
An anti-tumor agent that is commonly used as an apoptosis inducer, etoposide (VP-16) is a topoisomerase II inhibitor with an IC50 of 59.2 µM (1). Etoposide stabilizes a covalent topoisomerase II-cleaved DNA intermediate complex in the catalytic cycle of the enzyme, leading to genomic instability and cell death (2,3). This mechanism of action has been shown to delay progression of the cell cycle through the late S and early G2 phase (4,5).
- Terada, T. et al. (1993) J Med Chem 36, 1689-99.
- Baldwin, E.L. and Osheroff, N. (2005) Curr Med Chem Anticancer Agents 5, 363-72.
- Li, T.K. and Liu, L.F. (2001) Annu Rev Pharmacol Toxicol 41, 53-77.
- Dołega, A. (1998) Postepy Hig Med Dosw 52, 67-87.
- Smith, P.J. et al. (1994) Br J Cancer 70, 914-21.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.